Pfizer (PFE) Tops Q1 EPS by 12c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Pfizer (PFE) Target Increases at BMO Capital Following a Good Quarter
May 4, 2016 6:59 AM EDTBMO Capital analyst, Alex Arfaei, raised his PT on Pfizer (NYSE: PFE) to $40 (from $39) but admitted that much of the top-line beat was driven by more selling days in 1Q16 vs. 1Q15. Pfizers major growth drivers (e.g., Prevnar, Ibrance, Xeljanz, and Eliquis) all... More
